미국 · 보도자료 · GKOS · 2026-10-07 20:05
원추각막 치료제 '에피옥사(Epioxa®)', 3년 임상서 지속적 효과 입증
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the com
